Entinostat (MS-275, SNDX-275) is a potent HDAC inhibitor with IC50 of 0.3 and 8µM for HDAC1 and HDAC3, respectively. Entinostat (MS-275, SNDX-275) is synthetic benzamide derivative with potential antineoplastic activity. Entinostat (MS-275, SNDX-275) has no inhibitory activity towards HDAC8 (IC50>100 µM). Entinostat (MS-275, SNDX-275) appears to exert dose-dependent effects in human leukemia cells at low concentrations in human prostate cancer cell lines. Entinostat (MS-275, SNDX-275) exerted growth arrest in PC-3 and LNCaP cells, and induced cell death in DU-145 cells.

June 21, 2017

prudect name : Entinostat (MS-275, SNDX-275) is a potent HDAC inhibitor with IC50 of 0.3 and 8µM for HDAC1 and HDAC3, respectively. Entinostat (MS-275, SNDX-275) is synthetic benzamide derivative with potential antineoplastic activity. Entinostat (MS-275, SNDX-275) has no inhibitory activity towards HDAC8 (IC50>100 µM). Entinostat (MS-275, SNDX-275) appears to exert dose-dependent effects in human leukemia cells at low concentrations in human prostate cancer cell lines. Entinostat (MS-275, SNDX-275) exerted growth arrest in PC-3 and LNCaP cells, and induced cell death in DU-145 cells.
Entinostat (MS-275, SNDX-275)

Synonyms: Entinostat (MS-275, SNDX-275)CAS NO: 209783-80-2Molecular Formula: C₂₁H₂₀N₄O₃Molecular Weight: 376.41Purity: 98% minSolubility: In DMSOStorage: −20°C

Dicaffeoyltartaric acid References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18511937